Enzar-HS Capsule contains Pancreatin 250 mg, a combination of digestive enzymes including amylase, protease, and lipase, which aid in the breakdown of carbohydrates, proteins, and fats respectively. This medication is primarily indicated for patients with pancreatic exocrine insufficiency resulting from conditions such as chronic pancreatitis, cystic fibrosis, pancreatic surgery, or other disorders leading to inadequate pancreatic enzyme secretion. By supplementing endogenous enzymes, Enzar-HS facilitates improved digestion and nutrient absorption, thereby alleviating symptoms like steatorrhea, malabsorption, bloating, and abdominal discomfort. The capsule should be administered orally with meals or snacks to optimize enzymatic activity during digestion. Dosage must be individualized based on the severity of enzyme deficiency and patient response, and it is essential to follow medical guidance to avoid under- or overdosing. Enzar-HS is generally well tolerated; however, adverse effects may include gastrointestinal disturbances such as nausea, abdominal pain, or allergic reactions in rare cases. Caution is advised in patients with known hypersensitivity to pancreatin or its components. Regular monitoring of nutritional status and symptom improvement is recommended during therapy to ensure optimal clinical outcomes. Enzar-HS Capsule is a valuable therapeutic option for managing pancreatic enzyme insufficiency and improving quality of life in affected patients.